al. also reported similar results; a study conducted on NSCLC patients of a Caucasian population reported the prevalence of EGFR mutations in exons 18, 19, 20, and 21 to be 7.41%, 46.3%, 9.26%, and 37.04%, respectively. This evidence concerns the gene EGFR and non-small cell lung carcinoma.